As more biosimilars make their way to patients in the United States and Europe, stakeholders seek reassurance on switching to these products. A newly published systematic review sought to investigate the safety and efficacy of switching between reference and biosimilar infliximab in patients with inflammatory disorders.
As more biosimilars make their way to patients in the United States and Europe, stakeholders seek reassurance on switching to these products. A newly published systematic review sought to investigate the safety and efficacy of switching between reference and biosimilar infliximab in patients with inflammatory disorders.
The review, funded by Janssen, relies on English-language journal articles on biosimilar infliximab published between 2004 and 2018 that were identified through the MEDLINE database. The 36 studies eligible for inclusion all reported efficacy, safety, or immunogenicity data. Additionally, 34 abstracts from 2012 to 2017 were sourced from major meetings using the EMBASE database.
In total, 13 publications presented results from 6 randomized controlled trials of SB2 (Renflexis), CT-P13 (Inflectra), and BOW015 (an unapproved product developed by Epirus), and all 6 were single-transition studies:
An additional 53 publications report switching from reference infliximab to biosimilars in observational studies, but no studies report switching among biosimilars. Most uncontrolled studies did not report changes in safety, efficacy, or immunogenicity after a switch: “While several uncontrolled studies did report high rates of failure or discontinuation after transition, this was not consistently observed across studies,” write the authors.
Finally, 2 case studies reported lichenoid drug eruption and serum sickness-like disease in patients with CD and RA after switching to CT-P13, and a case series of 3 patients with Behçet disease reported loss of response after a switch to CT-P13. An additional case series reported maintained safety and efficacy in 9 patients with inflammatory bowel disease who switched to CT-P13.
“Overall, the evidence presented is this review is generally supportive of the safety and efficacy of one‐time switching between reference and biosimilar infliximab. However, after conducting this systematic review of the literature, we concluded that there was insufficient data to perform a meaningful meta‐analysis at this time,” conclude the authors. “Additionally, no studies have investigated multiple switching scenarios or switching between biosimilars, which may be representative of real‐world situations.”
Reference
Feagan BG, Lam G, Ma C, Lichtenstein GR. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.Aliment Pharmacol Ther.2018;1-10. doi: 10.1111/apt.14997.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.